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Introduction
Fever during chemotherapy-induced neutropenia 
continues to be a major cause of morbidity and mortality 
in cancer patients (Meunier et al.,1990). Although it is 
Potentially serious and may lead to a lethal outcome, 
yet many patients respond quickly to broad empiric 
spectrum antibiotic treatment and exibit an indolent 
course. However, 2 to 10% of patients develop severe 
complications and eventually die before resolution 
of the episode. Even for those patients who recover,it 
is also associated with increase in costs of anticancer 
treatments and may adversely affect patients quality of life. 
(Paesmans et al., 2007). Over the past few decades there 
has been considerable change in the pattern of pathogens 
causing infections in FN. Staphylococcus aureus was the 
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most frequent bacterial isolate from these patients in 1950s 
and early 1960s but was later replaced by Gram- negative 
bacilli organisms including Escherichia coli, Klebsiella 
species and Pseudomonas aeruginosa (Jones et al., 1999). 
However, since 1980s, resurgence of Gram-positive 
organisms is evident in these patient population (Sharma 
et al., 2005). Recently reports from developing countries 
have shown continued predominance of Gram negative 
bacilli in FN (Kanafani et al., 2007; Baskaran et al., 2007).
Mortality in FN has been shown to be associated with 
several factors like duration and degree of neutropenia, 
bacteremia, isolation of resistant organisms, identifiable 
focus (e.g., pneumonia, soft tissue infections, or catheter 
related infections), performance status, comorbidities, 
type and advance stage of underlying malignancy, etc. 
Though, these criteria are mostly used to stratify FN 
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episodes into low risk or high risk with implications for 
its management as inpatient or as outpatient , respectively 
(Klastersky et al., 2000) ; still, these are rather less well 
defined for those who are high-risk patient being treated 
as inpatient (Kuderer et al., 2006). 
The mortality rate for cancer patients with FN averaged 
9.3% per hospital database (range, 0% to 50%), with 
as much as 35.5% of institutions reporting mortality 
rates of 10% or greater.8 The overall mortality in our 
previous study was 13.7% (Osmani et al., 2012) . The 
highest mortality rates in cancer patients hospitalized 
with FN were observed with infections such as invasive 
fungal infections like, aspergillosis (39.2%) and invasive 
candidiasis (36.7%) followed by Gram-negative sepsis 
(33.9%), pneumonia (26.5%) or Gram-positive sepsis 
(21.2%), and those patients with major co-morbid 
conditions (Kuderer et al., 2006). 
The objective of the study is to present the available 
tools for risk assessment, and to review the patterns of 
pathogens in adult febrile neutropenic patients and to see 
their outcomes based on mortality. 
Materials and Methods
This cross sectional study was conducted on adult 
patients with culture positive FN admitted under 
Hematology/Oncology service at Aga Khan University 
Hospital, Karachi, Pakistan from 1st January 2009 to 
31st December 2012. The data set included patients 
demographics; age, sex and types of cancers; ANC at 
presentation; High-risk or low risk. High risk criteria were 
defined as: profound neutropenia (ANC <100/mm3), short 
latency from previous chemotherapy cycle (<10days), 
sepsis or clinically documented infection at presentation, 
severe co morbidity, performance status greater than or 
equal to 3 [Eastern Cooperative Oncology Group -ECOG-
scale. An ERC (Ethics Review Committee) approval 
was taken and later all the information was recorded 
on pretested Performa. All febrile neutropenic patients 
were treated initially empirically with broad spectrum 
intravenous antibiotics which were modified later based 
on culture results. However, decision of vancomycin and 
amphotericin B was according to established guidelines 
for the management of febrile neutropenia. All patients 
were managed in the oncology unit while neutropenic 
septic shock patients were managed in intensive care unit. 
The data was retrieved through the data was retrieved 
through hospital’s registration system and was analyzed 
by using Statistical Package for Social Sciences (SPSS) 
Version 19. Frequencies and percentages were computed 
for baseline characteristics, risk factors, bacterial isolates 
and outcome.
Results 
Total of 156 patients with culture positive febrile 
neutropenia were identified during the study period. The 
mean age was 47 (SD±11) years and there was a slight male 
predominance 54 % and females 46 % respectively. The 
proportion of distribution of patients was equal between 
solid and hematological malignancies. However, among 
Characteristics No. of Patients, n=156
Age in years 47 years (SD ±16)
Number of hospital stay in days 11 (SD ± 11)
Solid tumor 7.58 (SD±6.22)
Hematological Malignancy 14.95(SD±11.76)
Gender, Male/Female 84/72
Outcome  (Percentage)
     Alive 115 (74 %)
     Dead 41 (26%)
Cancer type:
Solid n=78  (50%)
     Head & Neck 08 (10%)
     Breast 14 (18%)
     Lung 07 (09%)
     Gastrointestinal malignancy 19 (24%)
     Genitourinary 16 (21%)
     Germ cell tumor 02 (03%)
     Sarcoma 09 (11%)
     Others 03 (04%)
Hematological malignancies n=78 (50%)
     Acute Myeloid leukemia 25 (32%)
     Acute lymphocytic leukemia 13 (17%)
     Lymphoma 36 (46%)
     Myeloma 01 (01%)
     Others 03 (04%)
     Prophylactic antibiotic 80 (51%)
     GCSF 36 (23%)
Risk factor
     High 116 (74)
     Low 40 (26)
     Profound neutropenia 65
     Short latency period 74
     Sepsis 30
     Performance status (PS 3-4) 8
     Comorbidity 3
No of high risk
     1 60 (52%)
     2 46 (40%)
     3 9 (8%)
     4 1 (0.8%)
Lines and catheters
     PICC 64 (41%)
     Porta Cath 19 (12%)
     Indwelling catheter 1 (0.6)
     PEG 2 (1%)
Culture
     Gram positive 53 (34%)
     Gram negative 89 (57%)
     Gram positive and negative 14 (9%)
Incidence of death, 41/ 156*100 = 26.2 per 100 patients  
Table 1. Baseline Demographic and Clinical 
Characteristics of Febrile Neutropenic Patients  
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uneventfully and discharged home. Overall mortality was 
26 percent : 32 in hematological and 21 percent in solid 
tumors respectively. The mean hospital stay of patients 
with solid tumor and hematological Malignancies were 
7.58 (SD±6.22) and 14.95(SD±11.776) days respectively. 
Mortality was higher in females and in patients with 
hematological malignancies i.e. 32 % (Table 2). 
23 deceased patients were already on prophylactic 
antibiotics at the time of presentation with febrile 
neutropenia. Mortality was higher in high risk group and in 
patients with both gram positive and negative bacteremia 
(Table 2 and 3). 
Discussion 
While evaluating 156 patients with FN with bacteremia 
we found 74% were high risk and mortality was slightly 
higher in this category. This was similar to the result of 
Carbonero et al study; patients with high risk had a higher 
incidence of prolonged neutropenia and serious medical 
complications and death than patients with no such risks 
(Carbonero et al., 2001). This study concurred with the 
previous study that the percentage of mortality gets 
higher with increase in number of risk factors. However, 
Carbonero’s study didn’t demonstrate whether patients 
were bacteremic or not. In another study, 26% of high 
risk patients were bacteremic with higher incidence of 
mortality when compared with non bacteremic group 
(Paesmans et al., 2007).
Majority of our bacteremic patients had acute leukemias 
which followed in frequency by lymphoma and other 
solid tumors. This was likely due to myelosuppressive 
chemotherapy which resulted in longer duration of 
neutropenia: a known risk of developing infections 
(Bodey et al., 1966). The mean hospital stay in FN was 
longer when compared with our contemporary study 
and reported literature this could probably be due to 
harboring of documented bacterial infection or high risk 
group or intrinsic low immunity of patients (Osmani et 
al., 2012; Berghmans et al., 2002). However, this cannot 
be ascertained due to retrospective nature of study; thus, 
a limitation of our study. Similarly mortality in FN with 
bacteremia was 26 % with slightly higher than seen in 
hematological malignancies due to prolonged neutropenia. 
hematological malignancies 49 percent patients had 
acute leukemias and 46 percent had lymphomas. Eighty 
patients were already on prophylactic antibiotics while 
36 patients received prophylactic granulocyte colony 
stimulating factors. Overall, 116 patients fulfilled the 
criteria for high risk group; 65 presenting with profound 
neutropenia, 74 with short latency period, 30 with sepsis, 
8 with poor performance status and 3 with co-morbid 
conditions. Fifty two percent had 1 high risk factor, 40 % 
had 2 high risk factors, 9% had 3 high risks factors while 
1 patient had all high-risk factors. All patients harbored 
either single or multiple bacterial organisms including 
gram positive, gram negative or both. 34% patients had 
gram positive bacteremia, 57 % with gram negative and 
9 % were infected with both gram positive and negative 
organisms (Table 1). 
Among 73 gram positive cultures 44 % were 
staphylococcus species 16 % were enterococcus and 
15 % were staphylococcus aureus, whereas among 123 
gram negative cultures 43 % were E. coli followed by 
Aeruginosa and klebsiella 18 and 17 % respectively 
(Table 4). 
Outcomes 
One hundred and fifteen patients recovered 
Variable Alive Deceased 
Gender    
     Male 66 (79%) 18 (21%)
     Female 49 (68%) 23 (32%)
Malignancy    
     Solid 62 (79%) 16 (21%)
     Hematological 53 (68%) 25 (32%)
     Prophylactic antibiotics 57(71%) 23 (29%)
Risk criteria    
     High 84 (72%) 32 (29%)
     Low 31(78%) 09(22%)
     Profound neutropenia 47 18
     Short latency period 51 23
     Sepsis 17 13
     Performance status 6 2
     Comorbidity  2 1
No of high risk   
     1 47 (78%) 13 (22%)
     2 30 (65%) 16 (35%)
     3 05 (56%) 04 (44%)
     4 1 0
Table 2. Outcomes of Febrile Neutropenic Patients with 
Bacteremia
Cultures   
Gram positive 41 (77%) 12 (23%)
Gram negative 64 (72%) 25 (28%)
Gram positive and negative 10 (71%) 04 (29%)
Table 3. Bacterial Cultures
Gram positive 
organism
N=73 Gram negative 
organism
N=123
Staphylococcus 
aureus
11(15%) E. coli 53 (43%)
staphylococcus spp 32(44%) P. Aureginosa 22(18%)
streptococcus spp 04(05%) Enterobacter 02(02%)
enterococcus spp. 12(16%) Klebsiella 18(17%)
bacillus spp. 07(10%) Acinetobacter 10(08%)
Nocardia 03(04%) Proteus 01(01%)
Corynebacterium 01(01%) Salmonella 03(02%)
Other gram+ve 
organism 03(04%)
Aeromonas 04(03%)
Stenotrophomonas 05(04%)
Others 05(04%)
Table 4. Spectrum of Bacterial Isolates  
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Lal’s study, also showed that bacteremia was significantly 
associated with increase length of hospital stay and 
mortality (Lal et al., 2008).
The spectrum of bacterial isolates was similar to 
what has been reported in both national and International 
literature i.e., Coagulase negative staphylococci were the 
most commonly isolated gram positive organisms (Butt et 
al., 2004; Blahova et al., 2004) and Escherichia coli was 
the most frequently isolated gram negative pathogen (Butt 
et al ., 2004; Sigurdardottir et al., 2005; Kirby et al., 2006).
Mortality was higher in patients with both gram 
positive and gram negative culture positive bacteremic 
patients followed by gram negative and lastly gram 
positive patients. Mortalities cannot be attributed to single 
organism as few patients had polymicrobial infection. 
The main concern regarding the use of prophylactic 
antibiotics remains the emergence of antibiotic resistance. 
There is no doubt that routine prophylactic use of 
antibiotics can cause colonization of individual patients 
with resistant organisms, but its clinical relevance 
unclear (M Cullen et al., 2009). We observed that half 
of our bacteremic patients were already on prophylactic 
antibiotics (Fluoroquinolones with or without Amoxicillin 
with clavulanic acid) which included all patients with 
acute leukemia receiving myeloablative treatment 
protocols. Despite that the mortality in this group was 
29%. As death from FN is relatively rare, meta-analyses 
are necessary to examine the effects of interventions on 
mortality. Gafter-Gvili et al, undertook a meta- analysis 
of trials comparing prophylactic antibiotic therapy 
(fluoroquinolone-based and other regimens) with placebo 
or no intervention in patients receiving chemotherapy. 
They analysed 95 randomized controlled trials conducted 
between 1973 and 2004 involving 9283 patients. The 
primary outcome was all-cause mortality, and secondary 
outcomes included infection-related death, febrile 
episodes, bacteremia, adverse events and emergence 
of bacterial resistance. This meta analysis showed a 
statistically significant reduction in all causes mortality 
of 34% in patients receiving prophylaxis compared 
with placebo or no intervention, and a 45% reduction in 
mortality in those receiving fluoroquinolones ( Gafter-
Gvili et al., 2005). 
In another meta-analysis included data from GIMEMA 
(Gruppo Italiano Malattie Ematologiche Maligne 
dell’Adulto) and the Significant Trial, Among patients 
with acute leukemia, one-third reduction as compared 
with the control group, who did not receive prophylaxis. 
Among patients with solid tumors and lymphomas, 
fluoroquinolone prophylaxis had a significant impact on 
all-cause mortality during initial cycle of chemotherapy, 
with a relative risk of 0.48 (0.26–0.88), compared with 
controls (Leibovici et al., 2006). 
In our study, since all acute leukemia patients were 
receiving prophylactic antibiotics, we did not have a 
control arm to show its benefits. In a recent study patients 
with low risk have shown benefits of using single agent 
moxifloxacin as prophylaxis when compared with either 
ciprofloxacin and Amoxicillin with clavulanic acid. 
Moxifloxacin is an extended-spectrum fluoroquinolone 
with a half life allowing convenient once-daily dosing. 
The drug is approved for pulmonary, skin/soft tissue, 
and intra-abdominal infections in many countries. When 
compared with ciprofloxacin, its antimicrobial activity 
against most Gram-positive bacteria is enhanced, 
whereas it has more limited activity against Pseudomonas 
aeruginosa (Kern et al., 2013) .
In conclusion, we emphasize the importance of risk 
stratification and continuous surveillance of the spectrum 
of locally prevalent pathogens and their susceptibility 
patterns which is essential for formulation of therapeutic 
regimens for chemotherapy induced febrile neutropenic 
patients. 
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